BIOGEN INC. Cost of Goods Sold (Deprecated 2018-01-31)
BIOGEN INC. (BIIB) reported Cost of Goods Sold (Deprecated 2018-01-31) of $446.00 million for the 3-month period ending 2018-03-31, per its 10-Q filed 2018-04-24.
Discontinued › Expense Statement › Cost of Sales
us-gaap:CostOfGoodsSold · last filed 2018-04-24
- BIOGEN INC. cost of goods sold (deprecated 2018-01-31) for the quarter ending 2018-03-31 was $446.00M, a 15.96% increase year-over-year.
- BIOGEN INC. cost of goods sold (deprecated 2018-01-31) for the quarter ending 2017-12-31 was $509.20M, a 34.53% increase year-over-year.
- BIOGEN INC. cost of goods sold (deprecated 2018-01-31) for the quarter ending 2017-09-30 was $370.00M, a 11.25% decline year-over-year.
- BIOGEN INC. cost of goods sold (deprecated 2018-01-31) for the quarter ending 2017-06-30 was $366.20M, a 1.11% decline year-over-year.
- BIOGEN INC. cost of goods sold (deprecated 2018-01-31) for fiscal 2017 was $1.63B, a 10.23% increase from fiscal 2016.
- BIOGEN INC. cost of goods sold (deprecated 2018-01-31) for fiscal 2016 was $1.48B, a 19.21% increase from fiscal 2015.
- BIOGEN INC. cost of goods sold (deprecated 2018-01-31) for fiscal 2015 was $1.24B, a 5.93% increase from fiscal 2014.
- BIOGEN INC. cost of goods sold (deprecated 2018-01-31) for fiscal 2014 was $1.17B, a 36.53% increase from fiscal 2013.
| Period end | Cost of Goods Sold (Deprecated 2018-01-31) 3 month | Cost of Goods Sold (Deprecated 2018-01-31) 3 month as first filed | Cost of Goods Sold (Deprecated 2018-01-31) 6 month | Cost of Goods Sold (Deprecated 2018-01-31) 6 month as first filed | Cost of Goods Sold (Deprecated 2018-01-31) 9 month | Cost of Goods Sold (Deprecated 2018-01-31) 9 month as first filed | Cost of Goods Sold (Deprecated 2018-01-31) 12 month | Cost of Goods Sold (Deprecated 2018-01-31) 12 month as first filed |
|---|---|---|---|---|---|---|---|---|
| 2018-03-31 | $446.00M 10-Q · filed 2018-04-24 | $955.20M derived: sum of 2 quarters · filed 2018-04-24 | $1.33B derived: sum of 3 quarters · filed 2018-04-24 | $1.69B derived: sum of 4 quarters · filed 2018-04-24 | ||||
| 2017-12-31 | $509.20M derived: 10-K 12 month − 10-Q 9 month · filed 2018-02-01 | $879.20M derived: sum of 2 quarters · filed 2018-02-01 | $1.25B derived: sum of 3 quarters · filed 2018-02-01 | $1.63B 10-K · filed 2018-02-01 | ||||
| 2017-09-30 | $370.00M 10-Q · filed 2017-10-24 | $736.20M derived: sum of 2 quarters · filed 2017-10-24 | $1.12B 10-Q · filed 2017-10-24 | $1.50B derived: sum of 4 quarters · filed 2018-04-24 | ||||
| 2017-06-30 | $366.20M 10-Q · filed 2017-07-25 | $750.80M 10-Q · filed 2017-07-25 | $1.13B derived: sum of 3 quarters · filed 2018-04-24 | $1.55B derived: sum of 4 quarters · filed 2018-04-24 | ||||
| 2017-03-31 | $384.60M 10-Q · filed 2018-04-24 | $763.10M derived: sum of 2 quarters · filed 2018-04-24 | $1.18B derived: sum of 3 quarters · filed 2018-04-24 | $1.55B derived: sum of 4 quarters · filed 2018-04-24 | ||||
| 2016-12-31 | $378.50M derived: 10-K 12 month − 10-Q 9 month · filed 2018-02-01 | $795.40M derived: sum of 2 quarters · filed 2018-02-01 | $1.17B derived: sum of 3 quarters · filed 2018-02-01 | $1.48B 10-K · filed 2018-02-01 | ||||
| 2016-09-30 | $416.90M 10-Q · filed 2017-10-24 | $787.20M derived: sum of 2 quarters · filed 2017-10-24 | $1.10B 10-Q · filed 2017-10-24 | $1.43B derived: sum of 4 quarters · filed 2018-02-01 | ||||
| 2016-06-30 | $370.30M 10-Q · filed 2017-07-25 | $683.30M 10-Q · filed 2017-07-25 | $1.02B derived: sum of 3 quarters · filed 2018-02-01 | $1.33B derived: sum of 4 quarters · filed 2018-02-01 | ||||
| 2016-03-31 | $313.00M 10-Q · filed 2017-04-25 | $644.80M derived: sum of 2 quarters · filed 2018-02-01 | $954.80M derived: sum of 3 quarters · filed 2018-02-01 | $1.24B derived: sum of 4 quarters · filed 2018-02-01 | ||||
| 2015-12-31 | $331.80M derived: 10-K 12 month − 10-Q 9 month · filed 2018-02-01 | $641.80M derived: sum of 2 quarters · filed 2018-02-01 | $927.90M derived: sum of 3 quarters · filed 2018-02-01 | $1.24B 10-K · filed 2018-02-01 | ||||
| 2015-09-30 | $310.00M 10-Q · filed 2016-10-26 | $310.03M 10-Q · filed 2015-10-21 | $596.10M derived: sum of 2 quarters · filed 2016-10-26 | $908.60M 10-Q · filed 2016-10-26 | $908.58M 10-Q · filed 2015-10-21 | $1.21B derived: sum of 4 quarters · filed 2017-02-02 | ||
| 2015-06-30 | $286.10M 10-Q · filed 2016-07-21 | $286.12M 10-Q · filed 2015-07-24 | $598.60M 10-Q · filed 2016-07-21 | $598.55M 10-Q · filed 2015-07-24 | $895.73M derived: sum of 3 quarters · filed 2017-02-02 | $1.20B derived: sum of 4 quarters · filed 2017-02-02 | ||
| 2015-03-31 | $312.40M 10-Q · filed 2016-04-21 | $312.43M 10-Q · filed 2015-04-24 | $609.63M derived: sum of 2 quarters · filed 2017-02-02 | $912.27M derived: sum of 3 quarters · filed 2017-02-02 | $1.20B derived: sum of 4 quarters · filed 2017-02-02 | |||
| 2014-12-31 | $297.23M derived: 10-K 12 month − 10-Q 9 month · filed 2017-02-02 | $599.87M derived: sum of 2 quarters · filed 2017-02-02 | $891.75M derived: sum of 3 quarters · filed 2017-02-02 | $1.17B 10-K · filed 2017-02-02 | $1.17B 10-K · filed 2015-02-04 | |||
| 2014-09-30 | $302.64M 10-Q · filed 2015-10-21 | $594.53M derived: sum of 2 quarters · filed 2015-10-21 | $873.77M 10-Q · filed 2015-10-21 | $1.13B derived: sum of 4 quarters · filed 2016-02-03 | ||||
| 2014-06-30 | $291.89M 10-Q · filed 2015-07-24 | $571.13M 10-Q · filed 2015-07-24 | $829.66M derived: sum of 3 quarters · filed 2016-02-03 | $1.06B derived: sum of 4 quarters · filed 2016-02-03 | ||||
| 2014-03-31 | $279.25M 10-Q · filed 2015-04-24 | $537.77M derived: sum of 2 quarters · filed 2016-02-03 | $772.47M derived: sum of 3 quarters · filed 2016-02-03 | $1.00B derived: sum of 4 quarters · filed 2016-02-03 | ||||
| 2013-12-31 | $258.53M derived: 10-K 12 month − 10-Q 9 month · filed 2016-02-03 | $493.22M derived: sum of 2 quarters · filed 2016-02-03 | $723.95M derived: sum of 3 quarters · filed 2016-02-03 | $857.70M 10-K · filed 2016-02-03 | $857.73M 10-K · filed 2014-02-06 | |||
| 2013-09-30 | $234.70M 10-Q · filed 2014-10-22 | $465.42M derived: sum of 2 quarters · filed 2014-10-22 | $599.17M 10-Q · filed 2014-10-22 | $733.00M derived: sum of 4 quarters · filed 2015-02-04 | ||||
| 2013-06-30 | $230.73M 10-Q · filed 2014-07-23 | $364.48M 10-Q · filed 2014-07-23 | $498.31M derived: sum of 3 quarters · filed 2015-02-04 | $637.66M derived: sum of 4 quarters · filed 2015-02-04 | ||||
| 2013-03-31 | $133.75M 10-Q · filed 2014-04-23 | $267.58M derived: sum of 2 quarters · filed 2015-02-04 | $406.94M derived: sum of 3 quarters · filed 2015-02-04 | $546.05M derived: sum of 4 quarters · filed 2015-02-04 | ||||
| 2012-12-31 | $133.83M derived: 10-K 12 month − 10-Q 9 month · filed 2015-02-04 | $273.19M derived: sum of 2 quarters · filed 2015-02-04 | $412.30M derived: sum of 3 quarters · filed 2015-02-04 | $545.49M 10-K · filed 2015-02-04 | ||||
| 2012-09-30 | $139.36M 10-Q · filed 2013-10-28 | $278.47M derived: sum of 2 quarters · filed 2013-10-28 | $411.67M 10-Q · filed 2013-10-28 | |||||
| 2012-06-30 | $139.11M 10-Q · filed 2013-07-25 | $272.31M 10-Q · filed 2013-07-25 | ||||||
| 2011-12-31 | $466.78M 10-K · filed 2014-02-06 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Revolution Medicines, Inc. (RVMD) | United States | $42.805B | -22.69 |
| EXELIXIS, INC. (EXEL) | United States | $14.358B | 16.15 |
| NEUROCRINE BIOSCIENCES INC (NBIX) | United States | $14.131B | 24.25 |
| HALOZYME THERAPEUTICS, INC. (HALO) | United States | $13.083B | 21.59 |
| Twist Bioscience Corp (TWST) | United States | $11.540B | -47.21 |
| BIO-TECHNE Corp (TECH) | United States | $11.379B | 74.68 |
| REPLIGEN CORP (RGEN) | United States | $10.755B | 185.31 |
| Krystal Biotech, Inc. (KRYS) | United States | $10.210B | 45.56 |
| Kymera Therapeutics, Inc. (KYMR) | United States | $9.631B | -31.69 |
| ImmunityBio, Inc. (IBRX) | United States | $9.157B | -9.29 |